
Opinion|Videos|December 8, 2023
EMERALD Subgroup Analysis in Patients with Coexisting PIK3CA and TP53 Mutations
Author(s)Hope S. Rugo, MD
Dr. Hope Rugo discusses EMERALD subgroup analysis, safety, and efficacy in patients with coexisting resistance mutations.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5










































